10 February 2022 | News
The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms
GenScript Biotech Corporation has announced the opening of a new facility for highly automated protein and gene preparation services, with $15 million investment.
Supported by the Singapore’s Economic Development Board (EDB), the new production site will support the Asia Pacific region and complements the current production sites in the United States and China.
The opening ceremony was held on a virtual setting, with IMAPAC as the marketing partner, inaugurated by Minister of State for Trade and Industry, and Culture, Community and Youth, Alvin Tan and accompanied by Senior Vice President and Head, Healthcare, Singapore Economic Development Board (EDB), Goh Wan Yee.
"The biomedical sector is critical to Singapore’s manufacturing ambitions, and the Government is committed to supporting the sector’s growth. We will do so by continuing to attract leading companies to Singapore, strengthening our existing base of companies, and growing our local enterprises. We will also invest heavily in R&D, and train local talent who can take advantage of the new opportunities and support the sector’s growth", said the Minister.
During the ceremony, GenScript and A*STAR Diagnostics Development Hub signed on a memorandum of understanding (MoU) to explore the possibility of collaborations for the purposes of building manufacturing capabilities in Singapore.
The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting edge facility in Singapore features a high throughput platform and proprietary technology of GenScript’s protein production to provide higher yield with a shorter turnaround time.
The capacity of the new facility could also be expanded to strengthen other business units to support cell and gene therapy and vaccine development in the region.